Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Free Cash Flow (2016 - 2025)

Fate Therapeutics' Free Cash Flow history spans 14 years, with the latest figure at -$28.9 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 1.25% year-over-year to -$28.9 million; the TTM value through Dec 2025 reached -$112.0 million, up 9.36%, while the annual FY2025 figure was -$112.0 million, 9.36% up from the prior year.
  • Free Cash Flow reached -$28.9 million in Q4 2025 per FATE's latest filing, down from -$22.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$22.2 million in Q3 2025 to a low of -$109.0 million in Q4 2022.
  • Average Free Cash Flow over 5 years is -$40.9 million, with a median of -$32.2 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: plummeted 180.92% in 2021, then skyrocketed 71.86% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$42.3 million in 2021, then plummeted by 157.43% to -$109.0 million in 2022, then surged by 71.86% to -$30.7 million in 2023, then increased by 7.02% to -$28.5 million in 2024, then decreased by 1.25% to -$28.9 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Free Cash Flow are -$28.9 million (Q4 2025), -$22.2 million (Q3 2025), and -$26.5 million (Q2 2025).